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In non-transformed cells Bak activates upon loss of
anti-apoptotic Bcl-XL and Mcl-1 but in the absence of
active BH3-only proteins
D Senft1,7, A Weber2,7, F Saathoff3,4, C Berking1, MV Heppt1, C Kammerbauer1, S Rothenfusser3,4,5, S Kellner1, Z Kurgyis1,6, R Besch1,8
and G Häcker*,2,8
Mitochondrial apoptosis is controlled by proteins of the B-cell lymphoma 2 (Bcl-2) family. Pro-apoptotic members of this family,
known as BH3-only proteins, initiate activation of the effectors Bcl-2-associated X protein (Bax) and Bcl-2 homologous antagonist/
killer (Bak), which is counteracted by anti-apoptotic family members. How the interactions of Bcl-2 proteins regulate cell death is
still not entirely clear. Here, we show that in the absence of extrinsic apoptotic stimuli Bak activates without detectable contribution
from BH3-only proteins, and cell survival depends on anti-apoptotic Bcl-2 molecules. All anti-apoptotic Bcl-2 proteins were
targeted via RNA interference alone or in combinations of two in primary human fibroblasts. Simultaneous targeting of B-cell
lymphoma-extra large and myeloid cell leukemia sequence 1 led to apoptosis in several cell types. Apoptosis depended on Bak
whereas Bax was dispensable. Activator BH3-only proteins were not required for apoptosis induction as apoptosis was unaltered
in the absence of all BH3-only proteins known to activate Bax or Bak directly, Bcl-2-interacting mediator of cell death, BH3-
interacting domain death agonist and p53-upregulated modulator of apoptosis. These findings argue for auto-activation of Bak in
the absence of anti-apoptotic Bcl-2 proteins and provide evidence of profound differences in the activation of Bax and Bak.
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The regulated elimination of cells by apoptosis is a key
mechanism of development, tissue homeostasis and defense.
In vertebrates, apoptosis is regulated through two pathways,
the death receptor-mediated (extrinsic) and the mitochondrial
(intrinsic) pathway, which is activated by numerous apoptotic
stimuli. Mitochondrial apoptosis is characterized by loss of
mitochondrial outer membrane integrity and the release of
mitochondrial intermembrane space proteins, most notably
cytochrome c, which leads to the activation of the caspase-9
and effector caspases.1
Release of cytochrome c is governed by proteins of the
B-cell lymphoma 2 (Bcl-2) family.2 The Bcl-2 family consists of
three groups, whose expression and interaction decide cell
survival. The anti-apoptotic Bcl-2 proteins include Bcl-2,
Bcl-XL (B-cell lymphoma-extra large), Bcl-w (Bcl-2-like protein 2),
Mcl-1 (myeloid cell leukemia sequence 1) and A1 (Bcl-2-
related protein A1). The pro-apoptotic group of BH3-only
proteins (containing a BH3-domain: Bim (Bcl-2-interacting
mediator of cell death), Bid (BH3-interacting domain death
agonist), Puma (p53-upregulated modulator of apoptosis),
Noxa (Phorbol-12-myristate-13-acetate-induced protein 1),
Bad (Bcl-2-associated death promoter), Bik (Bcl-2-interacting
killer) and Hrk (activator of apoptosis hara-kiri)) activate the
pro-apoptotic effectors Bcl-2-associated X protein (Bax) and
Bcl-2 homologous antagonist/killer (Bak). Bax and Bak can
replace each other in most situations, but the presence of one
of them is required for mitochondrial apoptosis. Upon
activation Bax and Bak form oligomers in the outer mitochon-
drial membrane and cause the release of cytochrome c. How
Bax and Bak are activated is still under debate. Different
activation models have been proposed and investigated.
According to the direct activation model BH3-only proteins
can directly, by physical interaction activate Bax and Bak.3
The model was derived in studies investigating synthetic
BH3-domain peptides in in vitro systems, that is, isolated
mitochondria or liposomes, where peptides encompassing the
BH3-domains of Bim or Bid (‘activator’ BH3-only proteins)
were able to activate Bax. Peptides derived from the BH3-only
proteins Bad, Bik, Hrk, Noxa or Puma did not activate Bax
directly. However, these peptides can bind to anti-apoptotic
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Bcl-2 proteins with varying preferences.4 As this may
neutralize a combination of anti-apoptotic proteins it may
facilitate Bax/Bak activation by activator BH3-only proteins.
Consequently, this group of BH3-only proteins has been
named ‘sensitizer’ or ‘derepressor’ BH3-only proteins.3,5–7
The direct activation model has received recent support by
structural studies of activator BH3-domains bound to Bax.8
That study also found that the BH3-only peptides
used previously lacked a residue that is important in the
activation of Bax, and the previous results may have to be
reconsidered. Indeed, a recent study illustrates that placing
the BH3-domain from the various BH3-only proteins into intact
Bid protein enhances Bax/Bak-activating capacity of the
BH3-domains of Bid, Bim, Puma, Bmf (Bcl-2-modifying factor),
Bik and Hrk.9
The displacement (or indirect activation) model on the
other hand posits that Bax and Bak are held in check by
anti-apoptotic Bcl-2 proteins and auto-activate when this
interaction is broken by BH3-only proteins (displacement).
BH3-only proteins can bind to anti-apoptotic Bcl-2 proteins
and upon apoptotic stimulationmay cause the displacement of
these proteins from Bax and Bak, which may lead to the
activation of effectors. BH3-peptides derived from Bim and
Puma can bind to all anti-apoptotic Bcl-2 proteins and its
corresponding proteins exert killing upon overexpression,
whereas Bad, Bmf, Bid, Bik, Hrk and Noxa display binding
patterns restricted to certain anti-apoptotic Bcl-2 proteins.4
It was therefore suggested that Bax/Bak activation requires
the neutralization/displacement of several anti-apoptotic
proteins, which may be achieved by one BH3-only protein
with broadly binding characteristics (such as Bim) or by the
combination of BH3-only proteins with restricted binding
capabilities (for instance Bad plus Noxa).10,11
The models have been further refined; the ‘embedded
together’model additionally considers the dynamic interaction
of the proteins with the mitochondrial membrane,12 and it has
been proposed that the models can be unified by taking two
‘modes’ of inhibition into account: anti-apoptotic Bcl-2 proteins
have a dual function in inactivating both, BH3-only proteins
and effectors. Pro-apoptotic signals cause the release of
activator BH3-only proteins from sequestration with anti-
apoptotic Bcl-2 proteins. Free BH3-only proteins directly
activate effectors, however, cell death may still not be initiated
because the effectors are then held in check by anti-apoptotic
Bcl-2 proteins. Free activator BH3-only proteins are required to
activate effectors.13
This model unifies the two above models in the sense that it
incorporates aspects of both, inhibition and displacement as
well as direct activation. However, the core difference between
the (direct) activation and the displacement model appears to
be irreconcilable: in the activation model Bax and Bak are
inactive unless receiving a stimulus from BH3-only proteins
whereas in the displacement model they are active unless
bound to anti-apoptotic proteins. Thus, in the absence of all
other proteins one model predicts that Bax/Bak are active, the
other that they are inactive. Obviously they cannot be both.
The direct activation model has initially been established
with Bax and the displacement model with Bak. The data are
very strong that Bax is activated by direct interaction with BH3-
only proteins. Recombinant Bak can also be directly activated
by recombinant tBid,14 and Bid/BH3-chimaeras can activate
recombinant Bak missing its C terminus.9 However, since Bak
is normally inserted into the outer mitochondrial membrane
where it may be bound to numerous other Bcl-2-family
members, it has been difficult directly to test activation of
Bak in the physiological situation.
One possibility to ‘unify’ the original models may be in a
model where Bax is physiologically activated by direct
activation (Bax is inactive until receiving a signal through
BH3-only proteins) whereas Bak is activated indirectly
(auto-activates when the inhibition by Bcl-2-like proteins is
relieved). Herewe test this possibility of indirect Bak activation.
We targeted anti-apoptotic Bcl-2 family proteins using RNAi.
In this setting, protein concentrations and conditions are
physiological, which avoids some of the problems associated
with overexpression or cell-free experiments. Non-malignant
cells may respond differently to the loss of anti-apoptotic Bcl-2
proteins compared with tumor cells.15 In this study, using non-
malignant cells, we targeted all anti-apoptotic Bcl-2 molecules
in combinations of two. In the absence of apoptotic stimuli we
observed that the combined loss of Bcl-XL and Mcl-1 was
sufficient to induce apoptosis. The direct activator proteins
Bid, Bim and Puma were not needed. These observations
provide evidence for indirect activation of Bak.
Results
Combined targeting of Bcl-XL and Mcl-1 induces
apoptosis in primary human cells. We recently investigated
anti-apoptotic Bcl-2 proteins to evaluate a strategy to induce
apoptosis in a tumor-specific way and observed that – in
contrast to tumor cells – targeting of a single anti-apoptotic
Bcl-2 protein by RNAi does not affect survival of primary
(non-transformed) human fibroblasts.15 To understand
whether any anti-apoptotic proteins are required for survival
we analysed the effect of combined simultaneous RNAi to
two anti-apoptotic Bcl-2 proteins. All combinations of two of
the anti-apoptotic Bcl-2 proteins, Bcl-2, Bcl-XL, Bcl-w, Mcl-1
and A1 were tested and efficient targeting of all proteins was
achieved (Figure 1a and ref. 15 for A1). Although most
combinations did not lead to significant cell death, targeting of
Bcl-XL and Mcl-1 killed ~ 60% of cells within 3 days
(Figure 1b; a less complete study in HeLa cells has also
reported that simultaneous targeting of Bcl-XL and Mcl-1
induces apoptosis16). To a lesser extent, targeting of Bcl-XL
and Bcl-w caused cell death, however, induction of Noxa was
observed there (data not shown). Noxa inactivates Mcl-1, and
experimental expression of Noxa sensitized the cells to RNAi
against Bcl-XL alone (see below). Cell death upon targeting of
Bcl-XL/Bcl-w may therefore not be due to the loss of Bcl-2-
function but the Noxa-mediated inactivation of Mcl-1, together
with RNAi against Bcl-XL; this targeting may thus have the
same molecular effect as RNAi against the combination of
Bcl-XL and Mcl-1. Therefore, the relevance of Bcl-XL/Bcl-w for
cell death cannot be addressed in this approach. Activation of
caspase-9 and caspase-3 was observed by western blotting
(Figure 1c). Cleavage of caspase-8 was also observed, which
very likely was subsequent to the activation of effector
caspases.
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To confirm this finding in another setting, we ectopically
expressed Noxa along with siRNA-mediated targeting of Bcl-
2, Bcl-XL and Bcl-w. Only upon targeting of Bcl-XL, Noxa
expression led to apoptosis. As Noxa specifically targets Mcl-1
this is additional evidence that specifically Mcl-1 inactivation
along with Bcl-XL targeting leads to cell death (Figure 1d).
Finally, we tested this combination in different cell types and
compared primary human fibroblasts (mesenchymal cells)
with primary human keratinocytes (epithelial cells) and
immortalized human microvascular endothelial cells.
Targeting of Bcl-XL and Mcl-1 caused cell death also in these
cell types (Figure 1e). These data show that specifically the
combined loss of Bcl-XL and Mcl-1 induces cell death in a
number of different primary cells without further stimulus.
Apoptosis upon targeting of Bcl-XL and Mcl-1 is mediated
by Bak. We next tested the relevance of the effector Bcl-2
proteins Bax and Bak for apoptosis induced by the loss of
Bcl-XL and Mcl-1. We were successful in knocking-down
expression of either effector together with Bcl-XL/Mcl-1
Figure 1 Combined inhibition of Bcl-XL and Mcl-1 induces apoptosis in primary cells. (a) Primary human fibroblasts were simultaneously transfected with two siRNAs as
indicated. Protein expression was measured 48 h after transfection by immunoblotting. α-Tubulin served as loading control. Results are representative of three independent
experiments. (b) Cell death of fibroblasts was measured by quantifying Annexin V- and propidium iodide (PI)-positive cells 3 days after siRNAs treatment. Data show means±S.D.
of three independent experiments. (c) Caspase activation in fibroblasts assessed by immunoblotting 48 h after siRNA treatment. Data are representative of two independent
experiments. (d) Fibroblasts were transfected with indicated siRNAs. Forty-eight hour after siRNA transfection cells were transfected with a Noxa-encoding or empty plasmid. Cell
death was measured 24 h after plasmid transfection. Data show means± S.D. of three independent experiments. (e) Cell viability was assessed 3 days after siRNA transfection in
primary human fibroblasts, primary human keratinocytes, and immortalized human microvascular endothelial cells (HMEC1). Data are given as means± S.D. of three
independent transfections. *Pr0.05
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(Figure 2a). Surprisingly, targeting of Bak almost completely
blocked cell death, whereas targeting of Bax had no
significant effect on cell death (Figure 2b). We also measured
the proportion of cells with activated Bax, using staining for
the 6A7 epitope in active Bax. Bax was found to be activated
upon targeting of Bcl-XL/Mcl-1 (Figure 2c). However, no
activation was seen when Bak had been targeted at the same
time, suggesting that Bax activation is secondary to Bak
activation but Bax cannot be activated in its absence
(Figure 2c).
Apoptosis upon targeting of Bcl-XL and Mcl-1 in murine
embryonic fibroblasts depends on Bak. To confirm Bak
dependency of apoptosis induced by the loss of Bcl-XL/Mcl-1,
we used murine embryonic fibroblasts (MEFs) WTor deficient
for Bak, Bax or double deficient for both. Knock-down of
Mcl-1 and Bcl- XL was also efficient in these cells (Figure 3a).
Similar to human fibroblasts, targeting of Bcl-XL/Mcl-1-
induced apoptosis in WT-MEFs, which was not observed in
Bax/Bak-DKO-MEFs (Figure 3b). Whereas apoptosis in
Bax-deficient MEFs was similar to the levels in WT-MEFs, it
was substantially reduced in Bak-deficient MEFs (Figure 3c).
There was a very small pro-apoptotic effect also in Bak-deficient
cells (Figure 3C). This may be a BH3-only protein-dependent
effect (for instance, the targeting of the anti-apoptotic proteins
may release some Bim), or it may be that in the absence of
Bcl-XL, which can retro-translocate Bax from mitochondria to
the cytosol,17 the accumulation of Bax at mitochondria will
have a small pro-apoptotic effect. The effect was however
minuscule compared to the effect of Bak (suggested by the
effect in Bax- versus Bak-deficient cell, Figure 3c).
We also tested Mcl-1-deficient MEFs. Here, targeting of
Bcl-XL was sufficient to induce cell death and again, cell death
was dependent on Bak, but not on Bax (Figure 3d). Together,
these results confirm the findings in murine embryonic
fibroblasts in different settings of Bcl-2 protein family deficiency.
Apoptosis upon Bcl-XL/Mcl-1 inhibition is initiated in the
absence of altered BH3-only protein expression levels.
Loss of Bcl-XL/Mcl-1 thus leads to the activation of Bak.
Figure 2 Apoptosis upon inhibition of Bcl-XL and Mcl-1 is mediated by Bak. (a) Primary human fibroblasts were transfected with indicated siRNAs. Protein expression was
measured 48 h after siRNA treatment. Results are representative of three independent experiments. (b) Fibroblasts were treated as described in a and cell death was quantified
3 days after transfection. Data are given as means± S.D. of three independent experiments. (c) Fibroblasts were treated as described in a and activation of Bax was quantified by
cytometry after staining with an antibody specific for activated Bax. Data show means±S.D. of at least three independent experiments. *Pr0.05; n.s., not significant
Bak activation by loss of Mcl-1 and Bcl-XL
D Senft et al
4
Cell Death and Disease
This could be due either to the liberation of Bak from these
two anti-apoptotic molecules or to the direct activation of Bak
by BH3-only proteins, which may either be released from
Bcl-XL/Mcl-1 or increased in expression. First, we tested
expression levels of BH3-only proteins with known capacity to
directly activate effector Bcl-2 proteins, namely Bim, Bid
and Puma. Bim-mRNA was not altered upon targeting of
Bcl-XL/Mcl-1 whereas protein levels were surprisingly
reduced (Figure 4a). Bid mRNA was not altered; however, a
slight reduction of Bid protein levels was observed, whereas
tBid was not detectable (Figure 4b). It cannot fully be
excluded that reduced Bid levels represent Bid activation
even in the absence of detectable tBid. We therefore tested
whether Bid levels were also reduced in the absence of Bak.
Bid levels were not found to be reduced upon targeting of Bak
(Figure 4b, right panel), suggesting that – if reduced Bid
levels represent Bid activation – Bid may be activated
downstream of Bak in an indirect manner but is not critical
for apoptosis induction. Basal Puma mRNA levels were not
significantly altered (Figure 4c) and Puma protein was not
detectable in these cells (data not shown). Levels of Noxa,
often regulated via transcription, were assessed by RT-PCR.
Noxa mRNA levels were increased, but in a Bak-dependent
manner suggesting an activation downstream of Bak
(Figure 4d). Noxa specifically antagonizes Mcl-1 and A1.4
Because Mcl-1 is already targeted by siRNA and combined
Bcl-XL/A1 inhibition did not lead to apoptosis (Figure 1b).
Noxa is unlikely to affect apoptosis upon Bcl-XL/Mcl-1-
siRNA treatment. No alteration of Bad or Bik mRNA
levels were observed (Figure 4e and f), whereas Hrk
was upregulated, however, in a Bak-dependent manner
(Figure 4g).
Together, the data suggest that most BH3-only proteins
are not induced. Some BH3-only proteins were induced in a
Bak-dependent way, suggesting that this induction is down-
stream of Bak. Therefore expression changes of these
molecules very likely do not function as a trigger for apoptosis
initiation.
Individual BH3-only proteins are not required for apop-
tosis induction upon loss of Bcl-XL/Mcl-1. To examine the
relevance of BH3-only proteins more rigorously, we tested
whether knock-down of BH3-only proteins affected apoptosis
upon targeting of Bcl-XL/Mcl-1. We silenced Bim, Bid, Bad or
Figure 3 Bak-dependent apoptosis upon inhibition of Bcl-XL and Mcl-1 in murine embryonic fibroblasts from knockout mice. (a) MEFs from Bax- or Bak-deficient, or WT mice
were treated with siRNAs for 3 days and protein expression was measured. Results are representative of three independent experiments. (b) MEFs from Bax/Bak-double-
deficient or WT mice were treated with siRNAs and cell death was analyzed 3 days after transfection. Data show means± S.D. of three independent experiments. (c) MEFs from
Bax- or Bak-deficient or WT mice were treated and analyzed as described in b. The small difference in cell death upon targeting Bcl-XL and Mcl-1 in Bak-deficient cells was
statistically significant (P= 0.048, control versus Bak-deficient cells). (d) MEFs from Mcl-1-deficient mice were treated with indicated siRNAs and analyzed 24 h after treatment.
Bcl-XL inhibition is sufficient in these cells to induce cell death. Data show means±S.D. of three independent experiments. *Pr0.05; n.s., not significant
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Puma by RNAi in human fibroblasts. siRNA treatment
strongly reduced the mRNA levels of the targeted gene
(Figure 5a). However, induction of apoptosis was not affected
when any of these molecules were targeted along with
Bcl-XL/Mcl-1 (Figure 5b). The studies were also extended to
Mcl-1-deficient MEFs, where two BH3-only proteins,
described to directly activate Bax or Bak, were targeted
simultaneously. No alteration of apoptosis induction was
observed (Figure 5c and d).
These data suggest that individual BH3-only proteins are
not required for apoptosis induced by loss of Bcl-XL andMcl-1,
further providing evidence that removal of Bcl-XL and Mcl-1 is
sufficient to induce cell death.
Apoptosis induced by Bcl-XL/Mcl-1 inhibition occurs in
absence of activator BH3-only proteins. We next tested
whether the combined inhibition of known activator BH3-only
proteins may affect cell death. We used Mcl-1-deficient MEFs
and successfully silenced Bim, Bid and Puma (Figure 6a).
Even simultaneous knock-down of these molecules did not
affect apoptosis induction (Figure 6b). We next used MEFs
deficient for Bim and Puma. Bcl-XL/Mcl-1 targeting induced
apoptosis to a similar extent as with WT-MEFs (Figure 6c).
Bid was then successfully targeted in these cells by siRNA,
providing a second cellular model in which all activator
BH3-only proteins are reduced (Figure 6d). Again, cell death
upon Bcl-XL/Mcl-1 targeting was not altered (Figure 6e).
Figure 4 Apoptosis upon Bcl-XL/Mcl-1 inhibition is initiated in the absence of altered BH3-only protein expression levels. (a) Primary human fibroblasts were treated with
Bcl-XL/Mcl-1 or Ctrl siRNAs. Expression of pro-apoptotic Bim was quantified 3 days after transfection on RNA (left panel) or protein level (right panel). Data show means±S.D.
and immunoblots are representative of three independent transfections. (b) Analysis of pro-apoptotic Bid in fibroblasts treated with indicated siRNAs for 3 days. Data show
means± S.D. and immunoblots are representative of three independent transfections. (c–g) Analysis of Puma, Noxa, Bad, Bik and Hrk in fibroblasts as described in b. Data show
means± S.D. and immunoblots are representative of three independent transfections
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The induction of apoptosis was confirmed by annexin
V-positive/propidium staining and by demonstrating the
activation of caspase-3 (Figure 6f). To rule out that any
activator BH3-only molecule is relevant for apoptosis upon
Bcl-XL/Mcl-1 loss, we generated MEFs that are triple deficient
for Bim, Puma and Bid. For this, CRISPR/Cas9 (clustered
regularly interspaced short palindromic repeats/endonu-
clease) was used to generate Bid-deficient cells on the basis
of Bim/Puma-knockout MEFs cells. Triple-knockout cells still
strongly underwent apoptosis when Bcl-XL/Mcl-1 were
targeted using different siRNA sequences (Figure 6g).
To further exclude the involvement of BH3-only proteins we
took advantage of a third experimental model and prepared
mitochondria from human fibroblasts treated with Bcl-XL-, Mcl-
1-, and Bak-specific siRNA. These cells survive due to the lack
of Bak (Figure 2a). If BH3-only proteinswere activated in these
cells, they would be localized at the membrane of the isolated
mitochondria and would be able to activate exogenously
added Bax, leading to release of cytochrome c. When active
Bim is overexpressed in Bax/Bak double-deficient mitochon-
dria, low levels (about 50 nM) of recombinant Bax are sufficient
to cause cytochrome c release.18 In mitochondria from
Bax/Bak double-deficient MEFs that had not been manipu-
lated, high levels (1000 nM) of recombinant Bax caused
release of cytochrome c (Figure 6h). However, even at this
high concentration Bax did not lead to release of cytochrome c
frommitochondria isolated from human fibroblasts treated with
siRNAs targeting Bcl-XL, Mcl-1, and Bak (Figure 6i). This
indicates that there is no active BH3-only protein at the
mitochondria that may have led to Bak activation, when cells
have lost Bcl-XL and Mcl-1.
Together these data demonstrate that even the loss of all
activator BH3-only proteins does not affect apoptosis induced
by inhibition of Bcl-XL and Mcl-1. Further, this occurs in the
absence of active BH3-only proteins at mitochondria. This
strongly suggests that BH3-only proteins are not involved in
apoptosis initiation upon loss of Bcl-XL and Mcl-1 in
these cells.
Discussion
Our results show that the removal of two anti-apoptotic
proteins in several non-malignant cell types activates Bak
Figure 5 Individual BH3-only proteins are not required for apoptosis induction upon loss of Bcl-XL/Mcl-1. (a) Primary human fibroblasts were transfected with Bcl-XL and Mcl-
1 siRNA together with control or siRNA specific for Bim, Bid, Puma or Bad as indicated. Respective gene expression was analyzed 24 h after transfection. (b) Primary human
fibroblasts were treated with siRNAs as indicated. Cell death was measured 3 days after transfection. (c) MEFs from Mcl-1-deficient mice were treated with two siRNAs as
indicated. mRNA levels were measured 24 h after transfection. (d) Mcl-1-deficient MEFs were transfected with two BH3-only targeting or control siRNAs as indicated. Forty-eight
hours after transfection, cells were transfected with Bcl-XL or control siRNAs and cell death was measured 24 h later. For a–d, data show means± S.D. of three independent
experiments. *Pr0.05; ND, not determined
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and subsequently causes apoptosis, which appeared not to
require BH3-only proteins. This suggests that Bak indeed can
auto-activate when this inhibition is removed. These results
may provide an explanation why cells express both Bax and
Bak despite their apparent biological redundancy.
Arguably, the activation of Bax is better understood than the
activation of Bak. Bax can be directly bound by BH3-domains
of Bim and Bid.8 Bax is normally inactive in the cytosol
but very likely can be activated by direct interaction with
the BH3-domain of BH3-only proteins. BH3-only proteins
Bak activation by loss of Mcl-1 and Bcl-XL
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(with the exception of Bad) are tail-anchored in the outer
mitochondrial membrane.7,18 It seems a likely model that Bax
can be activated by BH3-only proteins as it diffuses past the
mitochondrial membrane, where it inserts and triggers the
release of cytochrome c.
It may however not be appropriate to assume the same for
Bak. Bak is in the absence of apoptosis already inserted in the
OMM. Although Bak can in principle be activated by BH3-only
proteins and this may occur through direct binding, the
requirements for the activation of Bax versus Bak, with their
different spatial constraints, are likely different. Further, Bak
can bind Bcl-XL and Mcl-1 in principle,
10 and all three proteins
are at mitochondria; it therefore appears likely that there is
some binding in a normal, non-apoptotic cell.
Conversely, the indirect activation model is counter-intuitive
for Bax, with its primarily cytosolic localization: although the
potential binding to anti-apoptotic Bcl-2-proteins for Bax may
be suggestive,11 Bax is clearly at least predominantly
cytosolic. Accordingly, the studies of ‘displacement’ have
experimentally focused on Bak and have extrapolated the
findings to Bax. There is clear evidence that the activation of
Bax can involve a measure of displacement, or indirect
activation. This however is seen in situations where apoptosis
had been initiated but then blocked by anti-apoptotic Bcl-2
proteins. As elaborated on by the ‘unified model’ the inhibition
of active Bax and Bak is an important function of Bcl-2-like
proteins.
Indeed, this way of activation of Bax may be an important
difference between tumor cells and non-malignant cells. In
many cases tumor development creates the need for altera-
tions that help transformed cells escape defense mechanisms
of the host organism such as apoptosis.19 We have observed
previously that a cell lineage-specific expression profile of anti-
apoptotic Bcl-2 proteins is lost in tumor cells, which is
associated with increased dependency of tumor cells on these
proteins.15 Compared with cancer cells, the studies investigat-
ing anti-apoptotic Bcl-2 members in non-malignant cell are
less comprehensive.
In a study of cancer cells, where a small molecule library
was used to identify compounds inhibiting Mcl-1, Bcl-XL was
identified as the only marker predicting sensitivity to Mcl-1-
inhibiting compounds, and these small molecules induced
apoptosis via Bak not Bax.20 In the non-transformed cells we
used here only the simultaneous removal of Bcl-XL and Mcl-1
but not either on its own (or in combination with any other
Bcl-2-like protein) induced apoptosis. We observed this in
several non-malignant cell types, indicating a more common
survival regulation. This difference between cancer cells
and normal cells may be interpreted as an indication of a
pre-activated Bcl-2-system in tumor cells. In other cell types
this dependency may be different again. Mcl-1 is critically
required for the development and maintenance of many cells
of the hematopoietic system and it is sufficient to take away
Mcl-1 in mature lymphocytes to induce apoptosis.21
Together, our study provides evidence that Bak may be
activated independently of BH3-only proteins in non-malignant
cells. It therefore appears that Bak may auto-activate, and this
may be themain mechanism of its activation. Bax and Bak can
in many situations have the same activity and replace each
other, and there seems no plausible explanation why we have
two effector proteins that act exactly the same way. A different
mode of activation with Bax requiring activation through
BH3-only proteins and Bak auto-activating when the inhibition
is removed would appear to provide a reason for the presence
of both.
Materials and Methods
Reagents and antibodies. Anti–Bcl-2 (Ab-1) antibody was purchased from
Merck Biosciences (Darmstadt, Germany). Anti-Bcl-XL, anti-Bcl-w, anti-Bid, anti-Bim
(C34C5), anti-Bak, anti-caspase-3, anti-caspase-8 (1C12), anti-caspase-9 and HRP-
conjugated secondary antibodies were obtained from New England Biolabs (Berlin,
Germany). Anti-Mcl-1 (22) antibody was from BD Bioscience (Heidelberg, Germany),
anti-Bax (2D2) was from Santa Cruz Biotechnology (Heidelberg, Germany) and anti-
cytochrome c (clone 7H8.2C12) was purchased from BD Biosciences (Heidelberg,
Germany). Anti-β-actin (AC-15) and anti-α-tubulin (DM1A) antibodies were obtained
from Sigma-Aldrich (Munich, Germany). Bax activation was measured via flow
cytometry by staining with an antibody specific for the conformation of activated Bax
(Clone 3; BD Pharmingen, Heidelberg, Germany). PCR primers and siRNAs were
purchased from Eurofins MWG Operon (Ebersberg, Germany).
siRNAs. siRNAs were designed as described previously.22 Sequences of specific
siRNAs were A1 (human): GGAAGAAUUGUAACCAUAU, Bad (human):
GGATGAGTGACGAGTTTGT, Bak (human): GCTTCGTGGTCGACTTCAT, Bak
(mouse): ACACAGAGTTCCAGAATTT, Bax (human): GGGTTGTCGCCCTTTTCTA,
Bax (mouse): GATGAACTGGACAGCAATA, Bcl-2 (human): GGGAGAUAGUGA
UGAAGUA, Bcl-w (human): GGCAGACUUUGUAGGUUAU, Bcl-XL (human):
GGAACUCUAUGGGAACAAU, Bcl-XL (mouse): GCGTGGAAAGCGTAGACAA,
Bid (human): CTTGCTCCGTGATGTCTTT, Bid (mouse): CGACTGTCAACTT
TATTAA, Bim (human): GCAACCTTCTGATGTAAGT, Bim (mouse): GGAGACGA
Figure 6 Apoptosis induced by Bcl-XL/Mcl-1 inhibition occurs in absence of activator BH3-only proteins. (a) Mcl-1-deficient MEFs were treated with control siRNAs or siRNAs
targeting Puma, Bid, and Bim simultaneously. mRNA levels were measured 24 h after transfection. Data show means± S.D. of three independent experiments. (b) Mcl-1-deficient
MEFs were transfected with control siRNAs or siRNAs targeting Puma, Bid and Bim. Forty-eight hour after transfection, cells were transfected with Bcl-XL or control siRNAs and
cell death was measured 24 h later. Data show means± S.D. of three independent experiments. (c) MEFs from Bim/Puma-double-deficient or WT mice were transfected with Bcl-
XL and Mcl-1 or control siRNAs. Cell death was measured 3 days after transfection. (d) MEFs from Bim/Puma-double-deficient mice were transfected with control or Bid-specific
siRNA for 3 days. Then, cells were seeded and transfected with control, Bcl-XL-, Mcl-1- and Bid-specific siRNAs as indicated. Bid was quantified by immunoblotting 3 days after
the second transfection. Results are representative of three independent experiments. (e) Cell death was measured in Bim/Puma-double-deficient MEFs treated as described in d.
The mean percentage±S.D. of Annexin V-/propidium iodide-positive cells of three independent experiments is given. (f) Upper panel: representative histogram of Bim/Puma-double-
deficient MEFs treated as described in d indicating cells undergoing apoptosis as demonstrated by an Annexin V-positive/propidium iodide-negative cell population. Lower panel:
quantification of caspase-3 activation by immunoblotting. Results are representative of three independent experiments. (g) Bid/Bim/Puma-triple-deficient MEFs were transfected
with Bcl-XL- and Mcl-1-specific siRNAs or control siRNAs. Cell death was assessed after 48 h. For Bcl-XL and Mcl-1 two different siRNA sequences (siRNA a or b) were used in
different combinations. Inset shows result of knockout of Bid using CRISPR/CAS9 on Bim/Puma DKO MEF to generate triple KO cells. (h) Primary human fibroblasts were treated
simultaneously with Bcl-XL-, Mcl-1- and Bak-specific siRNAs. Three days after transfection mitochondria were prepared. Mitochondria were treated with recombinant Bax
(1000 nM) to stimulate cytochrome c (Cyt-c) release. Cyt-c release was assessed by immunoblotting in supernatant (SN) and mitochondrial (M) fractions. Tom40 (translocase of
the outer mitochondrial membrane protein 40) served as a control for mitochondria preparation. (i) Mitochondria of Bax/Bak-double-deficient MEFs were treated with recombinant
Bax. Cyt-c release was measured with 1000 nM Bax. A representative blot of two experiments is shown. *Pr0.05
Bak activation by loss of Mcl-1 and Bcl-XL
D Senft et al
9
Cell Death and Disease
GTTCAACGAAA, Mcl-1 (human): GGCAGUCGCUGGAGAUUAU, Mcl-1 (mouse):
GGGACTGGCTTGTCAAACA, Puma (human): CCGAGATGGAGCCCAATTA, and
Puma (mouse): AUGCACUGCUGUAGAUAUA. Depicted is the 19 nt portion
corresponding to the sense strand of the targeted mRNA. The sequence of the non-
silencing control siRNA (Ctrl) was GCGCAUUCCAGCUUACGUA.
Generation of Bim, Puma, Bid triple knockout MEF using
CRISPR/Cas9. Bid was specifically targeted in Bim/Puma double-deficient
MEF by using a two vector based CRISPR/CAS9 system kindly provided by Dr. Veit
Hornung (Institute of Molecular Medicine, University Hospital Bonn, Germany) by
transient transfection and subsequent selection. Efficacy was tested using antibody
against Bid.
Cell culture. Primary human fibroblasts and keratinocytes were isolated from
neonatal human foreskins. Cultivation of cells was described previously.23 Human
microvascular endothelial cells and immortalized murine embryonal fibroblasts
(MEFs) were cultivated in DMEM (Dulbecco’s modified Eagle’s medium) medium
supplemented with 10% FCS (fetal calf serum).
Transfection procedures. siRNA transfections were performed in 6-well
dishes in a volume of 1 ml utilizing Lipofectamine RNAiMAX (Invitrogen, Darmstadt,
Germany) according to the manufacturer’s protocol. For inhibition of a single gene,
20 nM siRNA together with 1.25 μl Lipofectamine RNAiMAX was used. For dual or
triple inhibition experiments, each specific siRNA was used in a concentration of
20 nM. The amount of control siRNA was adjusted to the total amount of specific
siRNAs used in the experiment as indicated in the figures. In dual inhibition
experiments 40 nM specific siRNAs or 40 nM control siRNA, in triple inhibition
experiments 60 nM siRNAs or 60 nM control siRNA was used together with 2 μl
Lipofectamine RNAiMAX. Plasmides were transfected at 1 μg/ml with 3 μl FuGENE
6 (Roche) according to the manufacturer’s protocol.
Quantification of viable cells. Viable cells with intact metabolism were
identified by their ability to reduce cell-permeable resazurin to fluorescent resorufin.
Medium was replaced with 750 μl of culture medium and 150 μl of CellTiter-Blue
reagent (CellTiter-Blue Cell Viability Assay; Promega, Mannheim, Germany). After
1 h incubation at 37 °C, fluorescence was measured.
Quantification of apoptotic cells and cell death. Adherent and
supernatant cells were analyzed by staining with FITC-labeled Annexin V (Roche,
Mannheim, Germany) and propidium iodide (Sigma-Aldrich) as described
previously.24 Cells were analyzed by fluorescence-activated cell sorting analysis
using CellQuest software (BD Bioscience).
RNA extraction and quantification. Total RNA was extracted from cells
using QIAzol Lysis Reagent (Qiagen, Hilden, Germany) as described by the
manufacturer and analyzed by quantitative RT-PCR. Reverse transcription and
quantification procedures using the LightCycler TaqMan Master Kit (Roche) together
with the Universal Probe Library system (Roche) were described previously.24
Relative gene expression was expressed as a ratio of the expression level of the
gene of interest to that of hypoxanthine phosphoribosyltransferase RNA determined
in the same sample.
Protein preparation and immunoblot analysis. Adherent and super-
natant cells were lysed in buffer containing 50 mM Tris, pH 7.4, 0.25 M NaCl, 1 mM
EDTA, 0.1% Triton X-100, phosphatase inhibitors (PhosSTOP, Roche) and protease
inhibitors (Complete, Mini, EDTA-free; Roche). Gel electrophoresis, blotting and
protein detection was carried out using the Xcell SureLock Mini-Cell apparatus
(Invitrogen) as described previously.24 Protein levels of β-actin or α-tubulin were
analyzed as a control for constant loading and transfer.
Isolation and treatment of mitochondria. Mitochondria were isolated
with a cell homogenizer (Isobiotec, Germany) pre-cooled on ice together with a
10 mm tungsten carbide ball inserted. The homogenizer was equilibrated with
isolation buffer (PBS supplemented with protease inhibitor cocktail for mammalian
cell (Sigma-Aldrich)). A total of 5 × 106 cells were resuspended in 1 ml of isolation
buffer and cell membranes were ruptured by passing the cell suspension three
times through the system. The homogenate was recovered by rinsing once with 1 ml
of isolation buffer and centrifuged (800 × g, 5 min at 4 °C) to remove cell debris and
nuclei. The supernatant was centrifuged at 9000 × g (10 min at 4 °C) and the
mitochondria-containing pellet was resuspended in 50 μl of isolation buffer. A total of
30 μg of the mitochondrial sample were centrifuged (9000 × g, 10 min at 4 °C) and
resuspended in 20 μl of KCl buffer (10 mM HEPES pH 7.4, 125 mM KCl, 4 mM
MgCl2, 5 mM KH2PO4 and 0.5 mM EGTA), supplemented with Bax as indicated in
respective experimental conditions. Mitochondria were incubated for 30 min at 30 °C
and mitochondria were pelleted at 9000 × g for 10 min at 4 °C. Supernatant was
collected and pelleted mitochondria were washed in 150 μl KCl buffer and
resuspended in 20 μl of KCl buffer. Supernatant and mitochondrial fractions were
analyzed by immunoblotting.
Statistics. For statistical analysis, two-tailed Student’s t-test was used to assess
the significance of mean differences. Differences were considered significant at a
P-value of 0.05 or less (indicated in the Figures (n.s., not significant; P40.05)).
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